Ultragenyx Pharmaceutical Inc.
RARE · XNASCIK 1515673fmd_05WHSA5VP05HDWX8DP3ZQAA0SVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 3 | 51 | 104 | 271 | 351 | 363 | 434 | 560 | 673 |
| Cost of revenue | – | 0 | 1 | – | – | – | – | – | – | – |
| Gross profit | – | 3 | 50 | – | – | – | – | – | – | – |
| Research and development | 183 | 232 | 294 | 357 | 412 | 497 | 706 | 648 | 698 | 750 |
| Selling, general and administrative | 65 | 100 | 128 | 162 | 183 | 220 | 278 | 310 | 321 | 349 |
| Total operating expenses | 248 | 332 | 423 | 528 | 601 | – | – | – | – | – |
| Operating income | (248) | (329) | (371) | (424) | (330) | (382) | (649) | (569) | (536) | (535) |
| Interest and investment income | 4 | 4 | 10 | 13 | 7 | 2 | 11 | 27 | 37 | 25 |
| Other non-operating income (expense) | 2 | 7 | (6) | (1) | 1 | (2) | (2) | (1) | (5) | 1 |
| Income before taxes | (246) | (318) | (197) | (399) | (185) | (453) | (702) | (609) | (567) | (571) |
| Income tax expense | 0 | (16) | 1 | 3 | 1 | 1 | 6 | (2) | 2 | 4 |
| Net income from continuing operations | (246) | (302) | (198) | (403) | (187) | (454) | (707) | (607) | (569) | (575) |
| Net income | (246) | (302) | (198) | (403) | (187) | (454) | (707) | (607) | (569) | (575) |
| Net income to common shareholders | (246) | – | – | – | – | – | – | – | – | – |